Breast cancer is the leading cause of cancer death in women around the world, responsible for 1,700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative ...
Jun 7, 2021
0
14
Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly. ...
May 3, 2021
0
4
Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic ...
Apr 27, 2021
0
196
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer. The scientists targeted a vulnerability ...
Apr 12, 2021
0
6
A significant proportion of hospitalized patients with influenza develop complications of acute respiratory distress syndrome, driven by virus-induced cytopathic effects as well as exaggerated host immune response. Reporting ...
Mar 16, 2021
0
9
In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming ...
Feb 10, 2021
0
64
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to ...
Jan 15, 2021
0
5
In a study in mice and human cells, Johns Hopkins Medicine researchers say that they have developed a tiny, yet effective method for preventing premature birth. The vaginally-delivered treatment contains nanosized (billionth ...
Jan 13, 2021
0
35
The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL). In an early benefit assessment, the German Institute for Quality and Efficiency ...
Jan 5, 2021
0
5
Researchers have identified acute myeloid leukemia as a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard ...
Oct 14, 2020
0
9
